Post Subject #360   0 NVS 3Q18 results: DewDiligence 10/18/18 04:05:46 PM #359   0 NVS receives CRL for Ilaris in CVD: #msg-144301592. DewDiligence 10/18/18 10:34:34 AM #358   0 NVS acquires ECYT for $2.1B: DewDiligence 10/18/18 10:33:30 AM #357   0 AMGN, NVS launch Humira biosimilars in Europe, pursuant DewDiligence 10/16/18 11:24:18 AM #356   0 ABBV settles global Humira-patent litigation with NVS: #msg-144157243. DewDiligence 10/11/18 05:24:02 PM #355   0 PDUFA date for NVS’ BAF312 in SPMS—>Mar 2019 DewDiligence 10/08/18 10:01:36 AM #354   0 Doctors and insurance companies will soon get wise DewDiligence 10/04/18 09:36:05 AM #353   0 Entresto will flop debunker1 10/04/18 06:10:41 AM #352   0 NVS sells US small-molecule-generics business to India’s Aurobindo DewDiligence 09/06/18 11:18:26 AM #351   0 NVS 2Q18 PR: DewDiligence 07/18/18 11:25:34 AM #350   0 NVS reports soft 2Q18—but re-iterates full-year guidance: DewDiligence 07/18/18 05:23:02 AM #348   0 NVS seeks to divest Alcon—will take enormous loss DewDiligence 06/29/18 09:39:31 AM #347   0 Entresto is nothing more than an attempt by debunker1 06/09/18 03:23:21 PM #346   0 NVS slides from “Meet the Management” Investor Day: DewDiligence 05/16/18 12:51:12 PM #345   0 Data support 12-week dosing of RTH258 for some DewDiligence 04/30/18 04:35:21 PM #344   0 FDA approves Tafinlar/Mekinist for adjuvant BRAF-V600+ melanoma: DewDiligence 04/30/18 04:22:15 PM #343   0 NVS acquires AVXS for $8.7B in cash: DewDiligence 04/09/18 02:55:20 PM #342   0 NVS PR on consumer-JV sale to GSK: DewDiligence 03/27/18 09:44:25 AM #341   0 NVS seeking bids for US small-molecule-generics business: DewDiligence 02/16/18 04:27:12 PM #340   0 :-) :-) :-) Ecomike 01/24/18 02:33:11 PM #339   0 NVS 4Q17 results… DewDiligence 01/24/18 09:10:05 AM #338   0 NVS hires oncology chief (from PFE): DewDiligence 01/11/18 10:40:04 AM #337   0 Novartis been researching PS Phosphatidylserine targeting ? biopharm 01/06/18 08:11:48 AM #336   0 The market is overvalued and overbought, and 2018's sokol 12/29/17 08:53:44 PM #335   0 NVS’ Investor Day PR and slides: DewDiligence 11/13/17 02:13:56 PM #334   0 https://seekingalpha.com/article/4124174-novartis-looks-challenge-regenerons-tur Inoviorulez 11/13/17 08:13:36 AM #333   0 NVS reports full dataset for RTH258-vs-Eylea phase-3 trials: #msg-136129447. DewDiligence 11/11/17 12:28:41 PM #332   0 NVS submits Kymriah BLA in adult DLBCL: #msg-135827815. DewDiligence 10/31/17 10:24:00 AM #331   0 NVS acquires AAAP for $82/ADS: #msg-135797034. DewDiligence 10/30/17 10:16:23 AM #330   0 Merging CRISPR editing and single cell sequencing technologies TERIA 10/26/17 12:20:15 PM #329   0 NVS 3Q17 CC slides: DewDiligence 10/24/17 06:57:02 PM #328   0 OK, thanks, also looks like it was a Ecomike 10/24/17 12:45:35 PM #327   0 NVS delayed the potential Alcon spin-off until 2019. DewDiligence 10/24/17 11:25:06 AM #326   0 Why the big drop in NVS today? Ecomike 10/24/17 11:14:32 AM #325   0 Vasant Narasimhan becomes CEO 2/1/18—succeeding Joe Jimenez: #msg-134366063. DewDiligence 09/04/17 10:41:21 AM #324   0 https://seekingalpha.com/article/4103595-novartis-history-made-future-cancer-tre Inoviorulez 09/01/17 07:42:32 PM #323   0 Kymriah/CAR-T outcomes-based pricing: #msg-134254831. DewDiligence 08/30/17 11:22:03 AM #322   0 FDA approves NVS’ Kymriah (CTL019 CAR-T) for pediatric ALL: DewDiligence 08/30/17 11:02:14 AM #321   0 New drug from Novartis helps prevent heart attacks biotech_researcher 08/27/17 07:51:53 AM #320   0 https://seekingalpha.com/article/4089618-amgen-novartis-first-mover-advantage-mu Inoviorulez 07/23/17 02:28:42 AM #319   0 Sell short this crap along with other big pharma... malt66 07/18/17 08:27:34 PM #317   0 NVS 2Q17 CC slides: DewDiligence 07/18/17 01:36:07 PM #316   0 https://seekingalpha.com/article/4087475-novartis-wins-fda-panel-backing-new-car Inoviorulez 07/13/17 10:07:15 AM #315   0 NVS’ own PR on CTL019 ODAC panel: DewDiligence 07/13/17 09:44:32 AM #314   0 FDA approves Tafinlar+Mekinist for BRAF-V600E NSCLC: #msg-132422635. DewDiligence 06/22/17 06:41:33 PM #313   0 Ilaris reduces MACE in secondary-prevention setting: #msg-132398529. DewDiligence 06/22/17 09:12:42 AM #312   0 RTH258 non-inferior to Eylea with less-frequent injections: #msg-132328161. DewDiligence 06/20/17 09:15:40 AM #311   0 EU approves NVS’ Rituxan FoB, called Rixathon: DewDiligence 06/19/17 11:43:31 AM #310   0 NVS “Meet the Management” Investor Day slides: DewDiligence 05/31/17 08:41:54 AM #309   0 CHMP approves Zykadia in first-line ALK+ NSCLC: DewDiligence 05/19/17 10:08:45 AM Post Subject

© 2018 InvestorsHub.com, Inc.